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ABSTRACT
Background
The epidermal growth factor receptor (EGFR) gene is the prototype member of the type I receptor
tyrosine kinase (TK) family and plays a pivotal role in cell proliferation and differentiation. There are
three well described polymorphisms that are associated with increased protein production in
experimental systems: a polymorphic dinucleotide repeat (CA simple sequence repeat 1 [CA-SSR1]) in
intron one (lower number of repeats) and two single nucleotide polymorphisms (SNPs) in the
promoter region, 216 (G/T or T/T) and 191 (C/A or A/A). The objective of this study was to examine
distributions of these three polymorphisms and their relationships to each other and to EGFR gene
mutations and allelic imbalance (AI) in non-small cell lung cancers.
Methods and Findings
We examined the frequencies of the three polymorphisms of EGFR in 556 resected lung cancers
and corresponding non-malignant lung tissues from 336 East Asians, 213 individuals of Northern
European descent, and seven of other ethnicities. We also studied the EGFR gene in 93
corresponding non-malignant lung tissue samples from European-descent patients from Italy and
in peripheral blood mononuclear cells from 250 normal healthy US individuals enrolled in
epidemiological studies including individuals of European descent, African–Americans, and
Mexican–Americans. We sequenced the four exons (18–21) of the TK domain known to harbor
activating mutations in tumors and examined the status of the CA-SSR1 alleles (presence of
heterozygosity, repeat number of the alleles, and relative amplification of one allele) and allele-
specific amplification of mutant tumors as determined by a standardized semiautomated method of
microsatellite analysis. Variant forms of SNP 216 (G/T or T/T) and SNP 191 (C/A or A/A) (associated
with higher protein production in experimental systems) were less frequent in East Asians than in
individuals of other ethnicities (p , 0.001). Both alleles of CA-SSR1 were significantly longer in East
Asians than in individuals of other ethnicities (p , 0.001). Expression studies using bronchial
epithelial cultures demonstrated a trend towards increased mRNA expression in cultures having the
variant SNP  216 G/T or T/T genotypes. Monoallelic amplification of the CA-SSR1 locus was present
in 30.6% of the informative cases and occurred more often in individuals of East Asian ethnicity. AI
was present in 44.4% (95% confidence interval: 34.1%–54.7%) of mutant tumors compared with
25.9% (20.6%–31.2%) of wild-type tumors (p ¼ 0.002). The shorter allele in tumors with AI in East
Asian individuals was selectively amplified (shorter allele dominant) more often in mutant tumors
(75.0%, 61.6%–88.4%) than in wild-type tumors (43.5%, 31.8%–55.2%, p ¼ 0.003). In addition, there
was a strong positive association between AI ratios of CA-SSR1 alleles and AI of mutant alleles.
Conclusions
The three polymorphisms associated with increased EGFR protein production (shorter CA-SSR1
length and variant forms of SNPs 216 and 191) were found to be rare in East Asians as compared
to other ethnicities, suggesting that the cells of East Asians may make relatively less intrinsic EGFR
protein. Interestingly, especially in tumors from patients of East Asian ethnicity, EGFR mutations were
found to favor the shorter allele of CA-SSR1, and selective amplification of the shorter allele of CA-
SSR1 occurred frequently in tumors harboring a mutation. These distinct molecular events targeting
the same allele would both be predicted to result in greater EGFR protein production and/or activity.
Our findings may help explain to some of the ethnic differences observed in mutational frequencies
and responses to TK inhibitors.
The Editors’ Summary of this article follows the references.
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Epidermal growth factor receptor (EGFR, also known as ERBB1)
belongs to the ERBB gene family of receptor tyrosine kinases
(TKs), and is a major regulator of several distinct and diverse
signaling pathways [1–3]. It is frequently overexpressed in
many malignancies including non-small cell lung cancer
(NSCLC), and overexpression may be associated with a
negative prognosis [4,5]. A recent ﬁnding that mutations of
the gene in lung cancers predict, somewhat imprecisely,
response to TK inhibitors (TKIs) has generated much interest
[6–10]. Mutations are limited to the ﬁrst four exons of the TK
domain, and occur more often in individuals with adeno-
carcinoma histology, East Asian origin, female gender, and
n e v e rs m o k e rs t a t u s .H o w e v e r, exceptions exist to the
correlation between mutation status and response to TKIs,
suggesting that other factors may play a role. Recently, EGFR
ampliﬁcation has been identiﬁed as a further factor that may
predict response to therapy [11,12]. Experimental evidence
indicates that polymorphisms of the gene may also regulate
protein expression.
CA simple sequence repeat 1 (CA-SSR1) is a highly polymorphic
locus containing 14–21 CA dinucleotide repeats and is
located at the 59 end of the long intron one of the EGFR
gene, lying upstream and in close proximity to a second
enhancer [13,14]. The allele size distribution of CA-SSR1
demonstrates ethnic differences, with East Asians having
longer repeats than individuals of European descent or
African–Americans [15]. By interacting with the second or
downstream enhancer, a lower CA-SSR1 repeat number was
found to modulate EGFR transcription in vivo and in vitro,
and to be correlated with increased transcription and protein
expression [13,14].
The relationship between CA-SSR1 repeat length and EGFR
overexpression has been extensively studied in breast cancers
[16,17]. Localized ampliﬁcation of the CA-SSR1 repeat, usually
limited to the shorter allele, occurs frequently in breast
cancers, is related to EGFR expression, and demonstrates a
ﬁeld effect, indicating that it is an early event during
multistage pathogenesis [18]. In head and neck cancer,
patients with a lower number of CA-SSR1 repeats (total of
both alleles , 35 repeats) had a statistically signiﬁcantly
increased likelihood of responding to erlotinib [19].
In addition to CA-SSR1, two kinds of single nucleotide
polymorphisms (SNPs) in the promoter region may correlate
with increased promoter activity and expression of EGFR
mRNA. One of the SNPs is located  216 bp upstream from
the initiator ATG (adenine as þ1), and the change of
nucleoside is guanine to thymine. This is an important
binding site for the transcription factor SP1 that is necessary
for activation of EGFR promoter activity [20]. The variant
forms,  216 G/T or T/T, are more frequent in individuals of
European descent and African–Americans than in Asians
[21]. The other SNP,  191 C/C, is located in the EGFR
promoter region near one of four transcription regions ( 214
to 200) [22]. This SNP may also be associated with increased
protein expression, and the minor forms, 191 C/A or A/A are
also rare among Asians [21].
For the reasons discussed above, we investigated the
distribution of these SNPs in lung cancer patients and
healthy individuals of various ethnicities, the length and
allelic imbalance (AI) of CA-SSR1 in lung cancer patients, and
the relationship between AI of CA-SSR1 and allele-speciﬁc
ampliﬁcation in lung cancer patients with mutations of the
EGFR gene.
Methods
Because of the multiple, complex studies performed in this
report, we summarize the salient investigations and their
results in Table 1.
Human Bronchial Epithelial Cell and Lung Cancer Cell
Lines
All cancer cell lines were cultured in RPMI 1640 (Life
Technologies, Rockville, Maryland, United States) supple-
mented with 5% fetal bovine serum and incubated in
humidiﬁed air and 5% CO2 at 37 8C. Most cell lines were
established by us at one of two locations. The preﬁx NCI
indicates cell lines established at the National Cancer
Institute, and the preﬁx HCC indicates cell lines established
at the Hamon Center for Therapeutic Oncology Research of
the University of Texas Southwestern Medical Center.
Human bronchial epithelial cells (HBECs) from healthy
individuals or those with lung cancer were immortalized and
cultured by us as previously described [23,24]. The cells were
cultured in K-SFM medium (Life Technologies) and included
5 ng/ml EGF.
Clinical Samples
A total of 556 samples of primary lung cancers including
adenocarcinomas (n¼345, 62%), squamous cell carcinomas (n
¼ 182, 33%), adenosquamous carcinomas (n ¼ 16, 3%), and
large cell carcinomas (n ¼ 10, 2%) were obtained from four
countries, the US, Australia, Japan, and Taiwan, and included
336 (60%) tumors from East Asians and 220 (40%) from other
ethnicities (97% of whom were of European descent). None
of the cases had prior treatment with TKIs. Samples of tumor
containing relatively high percentages of tumor (.70%) were
selected and analyzed without microdissection.
Corresponding non-malignant lung tissues were available
from 450 of the samples. We also obtained 93 DNA samples
from non-malignant lung tissue of European-descent patients
with lung cancer in Italy and 250 DNA samples of peripheral
blood mononuclear cells (PBMCs) from healthy individuals of
European descent (n ¼ 75), African–Americans (n ¼ 75), and
Mexican–Americans (n ¼ 100) enrolled in ongoing epidemio-
logical studies in the US for investigation of frequencies of
the polymorphisms (Table 2). Institutional Review Board
permission and informed consent were obtained at each
collection site.
DNA Extraction
Genomic DNA was isolated from cell lines, frozen primary
tumors, and non-malignant tissues by digestion with 100 lg/
ml proteinase K (Life Technologies) followed by standard
phenol-chloroform (1:1) extraction and ethanol precipitation
[25].
EGFR Gene Mutations
Details about EGFR mutation types and methodologies for
mutation detection have been published elsewhere [9].
Brieﬂy, we sequenced exons 18–21 of the TK domain of
EGFR in tumor and corresponding non-malignant tissues.
The overall frequency of mutation was 20%, and there were
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EGFR Polymorphisms in Lung Cancerthree kinds of mutations, in-frame deletions in exon 19,
missense mutations (predominantly mutation L858R in exon
21, but also in exons 18 or 20), and in-frame duplications/
insertions of one to three codons in exon 20. The resistance-
associated T790M mutation in exon 20 [9] was not detected in
any tumor.
Analysis of EGFR Polymorphic Sites
We sequenced genomic DNA encompassing the SNP sites
in the promoter region of EGFR  216 and  191 as described
previously [21], using a single PCR reaction.
The CA-repeat-containing region of intron one was
ampliﬁed by PCR. The sequences of the primers were 59-
CCA ACC AAA ATA TTA AAC CTG TCT T-39 (forward) and
59-CTT GAA CCA GGG ACA GCA AT-39 (reverse). For
analysis of repeat allele lengths and relative ratios, instru-
mentation and reagents from Applied Biosystems (Foster
City, California, United States) were utilized. The reverse
primer was labeled with TAMRA ﬂuorescent dye (6-FAM) at
the 59 end. The 25-ll PCR reaction mixture contained 100 ng
of genomic DNA, 103PCR buffer containing 15 mM MgCl2,2
mM of each dNTP, 10 pmol of each primer, and 1.25 units of
HotStart Taq DNA polymerase (Qiagen, Valencia, California,
United States). After an initial denaturalization step at 95 8C
for 12 min, samples were cycled 35 times as follows: 94 8C for
30 s, 60 8C for 30 s, and 72 8C for 30 s. The ﬁnal extension was
at 72 8C for 20 min. The size of the products (about 80 bp) was
Table 2. Summary of Germline (Blood) and Malignant and Non-Malignant Lung Tissues Examined
Sample Ethnicity Country Total
US Australia Japan Taiwan Italy
Healthy individuals without cancer Individuals of European descent 75 75
African–Americans 75 75
Mexican–Americans 100 100
Total 250 250
Non-malignant lung tissue from NSCLC patients Individuals of European descent 133 71 93 297
East Asians 4 1 187 48 240
Others 7 7
Total 144 72 187 48 93 544
Malignant lung tissue from NSCLC patients Individuals of European descent 142 71 213
East Asians 4 1 251 80 336
Others 7 7
Total 153 72 251 80 556
doi:10.1371/journal.pmed.0040125.t002
Table 1. Summary of Investigations Performed, Results, and Their Implications
Investigation Finding Implication
Ethnic differences in EGFR
polymorphisms in CA-SSR1 length
CA-SSR1 was longer in East Asians than in individuals
of European descent, both for shorter allele and for
combined allele length
For all three polymorphisms (shorter CA-SSR1
length and variant forms of SNPs  216 and  191),
the forms associated with increased EGFR protein
production are rarer in East Asians
Ethnic differences in EGFR
polymorphisms in SNP  216
Variant forms G/T and T/T were more common in
individuals of European descent
Ethnic differences in EGFR
polymorphisms in SNP  191
Variant forms C/A and A/A were more common in
individuals of European descent
Relationship between CA-SSR1
and SNP polymorphisms
NSCLC patients with rare forms of SNPs  216 and  191
had shorter combined allele length for CA-SSR1
The forms of the polymorphisms associated with
increased protein production tend to co-segregate
in lung cancer patients
Relationship between SNP  216
variants and EGFR mRNA expression
HBECs that have variant forms tended to make more
EGFR mRNA
For SNP  216, data are consistent with higher
protein production being associated with the minor form
Effect of CA-SSR1 allele length on
survival in patients with NSCLC
Patients with longer allele lengths had improved survival The data are consistent with the concept that patients
with less intrinsic protein production have improved
survival in the absence of TKI therapy
EGFR mutations in NSCLC Mutations were present in 25% of cases, and more
common in East Asians (35.6%) than in individuals of
European descent (11.3%)
This finding confirms previous reports that NSCLC
tumors in East Asians have a higher incidence of
EGFR mutations
Relationship between EGFR mutations
and CA-SSR1 AI
Mutations were more frequent in tumors with AI,
especially those arising in East Asians and those with SAD
Mutations and AI frequently occur together in East
Asian NSCLC tumors with SAD
Determination of whether AI targets
mutant or WT allele
In NSCLC cases having both AI and mutation, the copy
number of the mutant allele was preferentially increased
compared to that of the WT allele
AI preferentially targets the mutant allele
doi:10.1371/journal.pmed.0040125.t001
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EGFR Polymorphisms in Lung Cancerconﬁrmed by electrophoresis on 2% agarose gels. After PCR,
1 ll of the product plus 0.5 ll of Genescan 500 ROX
molecular weight standard were denatured in 12 ll of Hi-Di
Formamide (Applied Biosystems) and separated with a Prism
Genetic Analyzer and analyzed by Gene Scan Analysis
software 3.1 (Applied Biosystems).
Examination of the resultant traces demonstrated that
biallelic (heterozygous) samples showed two sets of waves and
two peaks, while the monoallelic (homozygous) samples
showed a single set of waves and one peak (Figure 1). The
highest peak reﬂects the repeat number of the CA-SSR1 allele
as determined by the size marker, while the preceding waves
(stutter bands) represent PCR-induced artifacts. In samples
without AI the shorter peak appears artiﬁcially larger as a
result of preferential PCR ampliﬁcation. In non-malignant
lung tissue the alleles were presumed to be of equal size, and
their ratios were used as a correction factor for this artiﬁcial
discrepancy.
The degree of the ampliﬁcation of each allele was indicated
by the area under the peak as determined by software
provided by the instrument’s manufacturer. The relative
ratios (AI ratios), termed LOH score in previous reports, of
the two peaks (shorter peak area under the curve to longer
peak area under the curve) in tumor samples were calculated
as previously described [26]. The AI ratio was calculated thus:
AI ratio ¼ (T1 3 N2)/(T2 3 N1), where T indicates tumor, N
indicates normal, 1 indicates the area under the peak for the
shorter allele, and 2 indicates the area under the peak for the
longer allele.
As either peak could be increased in relative size, AI cases
were divided into shorter allele dominant (SAD) or longer
allele dominant (LAD) cases. We used the deﬁnitions of these
two categories as determined previously [26]. SAD cases are
deﬁned as cases in which the adjusted AI ratio was greater
than 1.27, and LAD cases were those in which the adjusted AI
ratio was less than 0.79. For LAD cases, the formula results in
ratio values less than unity. Therefore, the ratio was inverted
for LAD cases, allowing the AI ratios to reﬂect the relative
size of the longer allele, irrespective of which allele was
increased in relative size. We conﬁrmed the previous ﬁnding
that the ratios of the areas under the curve for the two alleles
in constitutional DNA on repeat testing or from different
individuals are relatively constant. From an analysis of
constitutional DNA from over 500 healthy individuals and
cancer patients, we determined that the mean ratio of the two
alleles in non-malignant tissues was 1.3, resulting from
artiﬁcial preferential ampliﬁcation of the shorter allele (data
not shown). For tumor samples lacking corresponding non-
malignant tissue, the AI was determined by the formula AI
ratio ¼ T1/(T2 3 1.3).
The primers for investigation of selective ampliﬁcation of
the mutant or wild-type (WT) allele of exon 19 in-frame
deletions and the exon 21 point mutation L858R were
designed as follows: 59-TCA CAA TTG CCA GTT AAC GTC
T-39 (forward) and 59-CAG CAA AGC AGA AAC TCA CAT C-
39 (reverse) for exon 19, and 59-ATG AAC TAC TTG GAG
GAC CGT C-39 (forward) and 59-TGC CTC CTT CTG CAT
GGT ATT C-39 (reverse) for exon 21. Each forward primer
was labeled with TAMRA ﬂuorescent dye (6-FAM) at the 59
end. The conditions for PCR were the same as for CA-SSR1
except for the annealing temperature (57 8C for exon 19 and
61 8C for exon 21). The PCR products of exon 21 were cut by
Figure 1. Determination of AI for Heterozygous for CA-SSR1 and for Tumors Having a Deletion Mutation in Exon 19 or the L858R Mutation in Exon 21
Representative wave patterns are illustrated for (A) the CA-SSR1 allele and (B) the deletion mutation in exon 19 or L858R mutation in exon 21. Both
tumors and corresponding lung tissue were analyzed. Note in (A) the ratio of shorter allele to longer allele is actually 1.3:1, as illustrated for lung #423,
due to artifactual preferential amplification of the short allele. Thus, an appropriate correction factor is applied.
doi:10.1371/journal.pmed.0040125.g001
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Ipswich, Massachusetts, United States) and analyzed. The size
of each product (about 142 bp for mutant alleles of exon 19,
158 bp for the WT allele of exon 19, 100 bp for mutant the
allele of exon 21, and 150 bp for the WT allele of exon 21) was
also conﬁrmed by electrophoresis in 2% agarose gels.
The ratio (mutant allele/WT allele) to deﬁne ampliﬁcation
of each mutant allele, exon 19 in-frame deletion or the L858R
point mutation, was determined by ROC (receiver operating
characteristics) curves using the deﬁnitive value of AI, 1.27
(data not shown). The deﬁnitive ratios for exon 19 and 21
were 0.82 (sensitivity 70%, speciﬁcity 68%) and 0.2 (sensitivity
90%, speciﬁcity 90%), respectively, and the combined
deﬁnitive ratio was 0.47 (sensitivity 70%, speciﬁcity 61%).
We used these ratios as cut-off values to determine whether
the mutant allele was ampliﬁed. Because of the presence of
various amounts of non-malignant cells in the tumor samples,
ampliﬁcations of the WT allele could not be determined with
certainty.
Real-Time PCR for the Expression of EGFR mRNA
cDNA was prepared by reverse transcription of 2 lgo f
RNA from cell lines using SuperScript II reverse transcriptase
according to the manufacturer’s protocol (Invitrogen, Carls-
bad, California, United States). Real-time PCR was performed
with the Sybro (SYBR) Green I method using Power SYBR
Green PCR Master Mix (Applied Biosystems). ACTB cDNA
was used as an internal control. Primer sequences were as
follows: 59-ATA GTC GCC CAA AGT TCC GTG AGT-39
(forward) and 59-ACC ACG TCG TCC ATG TCT TCT TCA-39
(reverse) for EGFR and 59-AGT CCT GTG GCA TCC ACG
AAA CTA-39 (forward) and 59-ACT GTG TTG GCG TAC
AGG TCT TTG-39 (reverse) for ACTB. Standard curves for
EGFR and ACTB were obtained (Figure 2A), and the relative
expression ratios of EGFR:ACTB were calculated.
Figure 2. Relationship between SNP  216 Variants and EGFR mRNA Expression in HBEC Cultures
(A) Standard curves of EGFR and ACTB. Both slopes of cycle threshold (Ct)/log copies (Log Co) were mostly coincidental.
(B) Comparison of relative ratio of EGFR/ACTB among three groups of cultured cells (HBECs, lung cancer cell lines without EGFR mutations [WT], and lung
cancer cell lines with EGFR mutations [MU]).
(C) Comparison of relative ratio of HBECs having SNP  216 G/G versus G/T or T/T. mCA, mean number of CA-SSR1 repeats.
doi:10.1371/journal.pmed.0040125.g002
Table 3. The Distribution of EGFR Genotypes by Ethnicity for Lung Cancer Patients
NSCLC Patients SNP  216 SNP  191
G/G G/T or T/T p-Value
a C/C C/A or A/A p-Value
a
Individuals of European descent (n ¼ 306) 39.7% 60.3% ,0.001
b 63.0% 37.0% ,0.001
b
East Asians (n ¼ 331) 93.4% 6.6% 99.4% 0.6%
aChi-square test. No significant gender differences were present (p ¼ 0.194, Fisher’s exact test).
bGeneral linear regression adjusting for gender, age, smoking, histology, and EGFR mutations.
doi:10.1371/journal.pmed.0040125.t003
PLoS Medicine | www.plosmedicine.org April 2007 | Volume 4 | Issue 4 | e125 0719
EGFR Polymorphisms in Lung CancerStatistical Analyses
We used the Chi-square test (testing the null hypothesis of
equal distributions across study groups) to compare the
distributions across study groups when outcomes were
discrete such as genotypes of the SNP or SAD frequencies.
When events were rare, e.g., where the expected cell counts
were less than ﬁve, Fisher’s exact test was used instead for
comparisons. We also used Chi-square for an independent
test for the assessment of each ethnic group using the Hardy–
Weinberg equilibrium model. When outcomes were contin-
uous, such as CA-SSR1 repeat numbers, two-sample t-test and
analysis of variance were used. In order to control for
potential confounding bias in comparisons of SNP and CA-
SSR1 distributions, the multivariate logistic and general
linear regression models were used with certain clinicopa-
thological factors such as age, gender, smoking status, and
histology as covariates (Tables 3–6). AI ratios of CA-SSR1
plotted against mutant/WT ratios are shown in Figure 3 with
the ﬁtted regression lines. The associations between AI ratios
and mutant/WT ratios were tested using Pearson’s correlation
for exon 19, exon 21, and both combined. To be conservative
in case of small sample size and extreme values, the
nonparametric Wilcoxon rank sum test was used to compare
mutant/WT ratios for those with and without SAD. In this
paper, all statistical tests and 95% conﬁdence intervals are
two-sided. Because of multiple tests, p-values less than 0.01
were judged to be statistically signiﬁcant, and p-values less
than 0.05 were judged as moderately signiﬁcant. Both positive
and negative results are reported in the tables and in the text.
Results
Because of the complex nature of the ﬁndings and their
interrelationships, a tabular summary of our major ﬁndings is
presented in Table 1.
Ethnic Differences in Distribution of Polymorphisms
We examined ethnic differences in the distribution of the
minor alleles of the two SNPs 216 and 191 in the promoter
region of the EGFR gene and mean CA-SSR1 repeat numbers.
A summary of the samples studied from healthy individuals
and cancer patients is presented in Table 2. For healthy US
individuals, the frequencies of the  216 genotypes showed a
borderline statistically signiﬁcant difference between indi-
viduals of European descent, African–Americans, and Mex-
ican–Americans (p¼0.08) (Dataset S1). The G/G genotype was
present in 46.7% (95% conﬁdence interval: 35.4%–58.0%) of
individuals of European descent compared to 60% (48.9%–
71.1%) and 63% (53.5%–72.5%) of African–Americans and
Mexican–Americans, respectively. The frequencies of the
minor forms of the  191 polymorphism were signiﬁcantly
lower (p , 0.001) in African–Americans (10.7%, 3.7%–17.7%)
than in individuals of European descent (36%, 25.1%–46.9%)
and Mexican–Americans (43%, 33.3%–52.7%). Also, the
mean CA-SSR1 repeat number was signiﬁcantly shorter in
individuals of European descent (for the shorter, longer, or
combined allele lengths) than in African–Americans and
Mexican–Americans (combined allele length for individuals
of European descent, 35.3, 34.7–35.9, for African–Americans,
36.2, 35.6–36.8, and for Mexican–Americans, 36.8, 36.3–37.3; p
¼ 0.001). The differences between African–Americans and
Mexican–Americans were relatively modest and only reached
signiﬁcance for the shorter allele length (Dataset S1).
Among US European-descent individuals in this study,
there were no signiﬁcant differences in the frequency of the
three polymorphisms between the healthy individuals (DNA
from PBMCs) and those with NSCLC (DNA from non-
malignant tissue). As shown in Table 3 and Dataset S1, the
 216 G/G form was present in 46.7% (35.4%–58.0%) of the
healthy individuals and 39.7% (30.8%–47.4%) of the patients
with lung cancer (p ¼ 0.321), and the  191 C/C genotype was
Table 4. Ethnic Differences in Distribution of the Allele Lengths of CA-SSR1 in Lung Cancer Patients
NSCLC Patients Shorter Allele Length Longer Allele Length Combined Allele Length
Mean (SD) p-Value
a Mean (SD) p-Value
a Mean (SD) p-Value
a
Individuals of European descent (n ¼ 306) 16.6 (1.4) ,0.001
b 18.5 (1.8) ,0.001
b 35.1 (2.8) ,0.001
b
East Asians (n ¼ 331) 17.9 (2.0) 19.8 (1.2) 37.7 (2.7)
aTwo-sample t-test. No significant gender differences were present (p ¼ 0.194, Fisher’s exact test). Therefore, gender is not adjusted for in the comparisons.
bGeneral linear regression adjusting for gender, age, smoking, histology, and EGFR mutations.
SD, standard deviation.
doi:10.1371/journal.pmed.0040125.t004
Table 5. The Relationship between Repeat Length of CA-SSR1 and SNPs
CA-SSR1 Allele SNP  216 SNP  191
G/G G/T or T/T p-Value
a C/C C/A or A/A p-Value
a
Shorter 17.7 (1.9) 16.3 (1.0) ,0.001 17.3 (1.9) 16.8 (1.2) 0.084
Longer 19.6 (1.3) 18.2 (1.8) ,0.001 19.2 (1.7) 18.8 (1.3) 0.011
Combined 37.3 (2.8) 34.5 (2.4) ,0.001 36.6 (3.1) 35.6 (2.3) 0.011
Data are given as mean repeat length (standard deviation).
aTwo-sample t-test after adjustment for ethnicity.
doi:10.1371/journal.pmed.0040125.t005
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EGFR Polymorphisms in Lung Cancerpresent in 64% (53.1%–74.9%) of the healthy individuals and
63% (54.8%–71.2%) of the patients with cancer (p ¼ 0.941).
Also, the mean CA-SSR1 repeat numbers for the short allele,
long allele, and combined alleles of healthy European-descent
individuals were not signiﬁcantly different from those of
European-descent patients with cancer (p ¼ 0.492, 0.604, and
0.495, respectively) (Table 4; Dataset S1). These data
permitted us to presume that the polymorphism frequencies
in patients with lung cancer follow the pattern of the general
population, and we can combine the data from healthy
individuals and patients with NSCLC for individuals of
European descent, which is the dominant ethnicity of the
US, Italy, and Australia populations in this study. Further-
more, no signiﬁcant differences were observed in this study
for the frequencies of all three polymorphisms between
individuals of European descent in the US versus in Italy, nor
between East Asians in Japan versus in Taiwan (data not
shown). Thus, we pooled the data from these two groups and
labeled them as ‘‘individuals of European descent’’ and ‘‘East
Asians,’’ which were then used for further analyses.
Comparing individuals of European descent and East
Asians, the frequency of the minor forms of the  216
polymorphism was signiﬁcantly higher (p , 0.001) in
individuals of European descent (60.3%, 54.8%–65.8%) than
in East Asians (6.6%, 3.9%–9.3%). This was also true for the
minor forms of the  191 polymorphism (individuals of
European descent, 37.0%, 31.6%–42.4%; East Asians, 0.6%,
0%–1.4%; p , 0.001), as shown in Table 3. In addition, Table
4 shows that both alleles of CA-SSR1 (and the combined allele
length) were signiﬁcantly shorter in individuals of European
descent than in East Asians (p , 0.001). The comparisons
were controlled for potential confounders such as gender,
age, and smoking.
Relationship between CA-SSR1 Allele Lengths and SNPs
We ﬁrst examined the concordance of the SNP  216, SNP
 191, and CA-SSR repeat polymorphisms. As shown in Table
5, individuals who were homo- or heterozygous for the
variant forms of SNP  216 (G/T or T/T) had signiﬁcantly
lower mean CA-SSR repeat numbers in short, long, and
combined allele lengths than those who were homozygous for
the common form 216 G/G after adjustment for ethnicity. In
similar comparisons for the variant forms of SNP 191, there
was signiﬁcant concordance with the longer and combined
allele lengths, but not for the shorter allele.
We next investigated the relationship between the com-
bined allele length and the SNPs for different ethnicities. For
convenience, since the overall mean CA-SSR1 repeat number
for shorter and longer allele combined was 36, we dichotom-
ized the combined allele length as ‘‘longer’’ for those with
greater than 36 repeats and as ‘‘shorter’’ for those with 36
repeats or fewer. As shown in Table 6, the frequency of the
‘‘shorter’’ combined allele was signiﬁcantly higher in individ-
uals with the minor forms of  216 (East Asians, 72.7%,
54.1%–91.3%; individuals of European descent, 81.2%,
76.1%–86.3%) than in those with the common form (East
Asians, 36.6%, 30.9%–41.7%; individuals of European de-
scent, 53.7%, 45.8%–61.6%). A similar pattern for SNP  191
was noted in East Asians but not in individuals of European
descent. Also, for individuals carrying both variant genotypes
of the two SNPs, the frequency of the ‘‘shorter’’ combined
allele was observed to be higher than in those with the
common forms of the SNPs in both individuals of European
descent and East Asians, although the difference was statisti-
cally signiﬁcant only in East Asians (Dataset S2).
Relationship between EGFR Expression and the  216
Polymorphism
The polymorphism genotype of the 11 HBEC cultures was
determined as previously described. The lines, derived from
American individuals of European descent, showed little
variation in the repeat length of the shorter CA-SSR1 allele
(mean length 16.2, range 16–17). Similarly, for the  191
polymorphism, ten of the cases had the common C/C
genotype and only one case demonstrated the C/A genotype.
Thus, we were unable to study the effects of these two
polymorphisms on gene expression in the HBEC cultures.
However, for the  216 polymorphism, four of the cases had
the common form, G/G, while the remaining seven cases
expressed the variant forms G/T (n ¼ 5) or T/T (n ¼ 2). Thus,
we limited our examination of the relationship of SNPs to
EGFR expression to the  216 polymorphism (Figure 2B and
2C).
The standard curves for ACTB and EGFR mRNA expression
were straight lines nearly parallel to each other (Figure 2A),
permitting us to use the expression ratio of these two genes
for comparisons. To further validate our assays, we deter-
mined the ratios for the HBECs as well as for eight NSCLC
cell lines having the WT form and for seven cell lines having a
mutant form of the EGFR gene. As expression in normal
Table 6. Ethnic Differences in the Relationship between the Length of CA-SSR1 and SNPs  191 and  216
SNP Genotype East Asians Individuals of European Descent
Percentage with Shorter Combined CA-SSR1
a p-Value
b Percentage with Shorter Combined CA-SSR1
a p-Value
b
 216 G/G 36.3% 0.001 53.7% ,0.001
G/T or T/T 72.7% 81.2%
 191 C/C 38.3% 0.149 76.2% 0.017
C/A or A/A 100.0% 59.5%
Both C/C þ G/G 35.8% ,0.001 59.0% 0.119
Others 75.0% 72.7%
aHaving a shorter combined allele is defined as having 36 or fewer combined CA-SSR1 repeats. (This cut-off is based on the overall mean length of the combined allele for both ethnic
groups. Using the individual group means for East Asians and individuals of European descent as the cut-offs shows the similar results.)
bp-Values are from Fisher’s exact tests.
doi:10.1371/journal.pmed.0040125.t006
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ligand, the HBECs were cultured in EGF-containing medium
(5 ng/ml). Expression in the HBECs was relatively low, with a
narrow range (Figure 2B). The lung cancer lines, grown in the
absence of added ligand, showed considerable variability of
expression. Four WT lines had low expression, while four
lines, all having EGFR copy number of four or greater, had
considerably higher expression levels. Four of the mutant
lines, all highly ampliﬁed for copy number and lacking the
secondary resistance-associated T790M mutation [27,28], had
high expression ratios. However three mutant lines had low
expression ratios. Two of these lines had the secondary
T790M mutation as well as an activating mutation, while the
third line had a relatively low copy number.
While the range of expression in the HBECs was modest, we
correlated expression with the  216 genotype (Figure 2C).
The four lines having the G/G phenotype had a mean
expression ratio of 1.0 (range 0.5–1.3). The seven lines having
one of the two variant forms had a mean expression ratio of
1.2 (range 1.0–1.7). The two lines homozygous for the variant
form T/T were among the three highest expressing lines.
While these differences were not signiﬁcant, they may
represent a trend towards higher expression being associated
with the variant forms.
The range of relative expression of EGFR compared to
ACTB of lung cancer cell lines was variable. The two high
values were observed in the cell lines with EGFR mutation.
The mean value of cell lines having the common SNP 216 G/
G( n ¼ 4) was 0.97, compared to 1.24 for the lines with the
minor forms SNP  216 G/T or T/T (n ¼ 7) (Figure 2C). The
range of the number of CA-SSR1 repeats in the cell lines, all
from individuals of European descent, was from 16 to 17 for
the shorter allele, 16 to 19 for the longer allele, and 32 to 38
for the combined length. The highest value was observed in
the group with the shortest combined number of CA-SSR1
repeats (32) and one of the minor SNP  216 forms.
The Relationship between Polymorphisms and Survival
We also investigated the relationship between the SNP
 216, SNP  191, and CA-SSR repeat polymorphisms and
patient overall survival (Figure S1). We did not observe a
relationship between survival and either SNP form or any
combination of SNP forms after adjusting for age, gender,
ethnicity, smoking, and histology. For the shorter allele of CA-
SSR1 in the tumor cases, the mean length was 17.5. We
divided the cases into those having shorter alleles, with mean
lengths of 17 or fewer repeats, and those having a mean
length of 18 or more repeats. We found that cases having a
mean length of 18 or more repeats had improved survival
compared to those having shorter allele lengths of 17 or fewer
repeats (p¼0.017). These ﬁndings suggest that patients (in the
absence of TKI therapy) whose tumor cells are predicted to
make less EGFR protein have an improved survival compared
to those whose cells are predicted to have higher intrinsic
protein production. Similar data have been reported recently
from another group [29]. For cases with AI of CA-SSR1 (see
below) or of the mutant allele, no differences in patient
survival were noted (data not shown).
AI of the CA-SSR1 Alleles
The degree of ampliﬁcation of each allele was reﬂected by
the relative area under the peak (Figure 1), and the AI was
determined by the ratio of shorter to longer CA-SSR1 alleles
in informative cases where two alleles were of different
length. Among 450 tumor cases where the corresponding
non-malignant lung tissues were available, there was no
difference in the presence of homo- or heterozygosity of
allele length or in the repeat length of each allele between
tumor and non-malignant tissues (data not shown). These
ﬁndings permitted us to analyze all 556 cases using the tumor
tissues alone. For the CA-SSR1 alleles, 376 (68%) of 556 cases
were informative. The informative rate was similar to that in
other previous studies [16,26]. However, in our study the
Figure 3. The Correlation between AI and Allelic Ratio
The correlation between allelic ratio of CA-SSR1 (shorter allele/longer allele) and the allelic ratio (AR) of mutant (MU) to WT allele of (A) the exon 19 in-
frame deletion (r
2¼0.394, p¼0.011), (B) the exon 21 L858R point mutation (r
2¼0.927, p , 0.001), or (C) both (r
2¼0.594, p , 0.001) in the same mutant
cases.
doi:10.1371/journal.pmed.0040125.g003
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was an informative rate of 62.8 % (211/336) in East Asians and
75.0% (165/220) in other ethnicities. Of the 376 informative
cases, we excluded cases with mutations other than deletions
in exon 19 or the L858R mutation in exon 21 (n ¼12) as well
as patients of ethnicities other than East Asians and
individuals of European descent (n ¼ 5) and Asians in the
US (n ¼ 3). Of the remaining 356 NSCLC cases of East Asian
or European descent, 263 had the WT EGFR gene and 95 had
the mutations in exon 19 or exon 21.
For these 356 cases, we determined the ratios of the CA-
SSR1 alleles as previously described in the Methods section.
AI, deﬁned by an allelic ratio greater than 1.27 or less than
0.79, was present in 109 (30.6 %) of the cases but was
signiﬁcantly more frequent (p ¼ 0.002) in cases with mutant
tumors (44.4%, 34.1%–54.7%) than in those with WT tumors
(25.9%, 20.6%–31.2%), and in East Asians (35.6%, 29.0%–
42.2%) than in individuals of European descent (23.8%,
17.0%–30.6%) (p ¼ 0.019) (Table 7; Dataset S3).
The 109 cases with AI were also divided into SAD or LAD.
As shown in Table 8 (and Dataset S3), the overall frequency of
SAD was 60.3% (49.1%–71.5%) in East Asians and 44.4%
(28.2%–60.6%) in individuals of European descent. Also, in
East Asians the SAD frequency was signiﬁcantly higher (p ¼
0.001) in tumors with the exon 19 or exon 21 mutation than
in those without mutations (82.4%, 69.6%–95.2%, versus
41.0%, 25.6%–56.4%). This difference, however, was not
observed in patients of European descent.
AI of Mutant to WT Allele
For cases with the deletions in exon 19 or the L858R
mutation in exon 21, the AI of the mutant allele was
determined by the mutant/WT allele ratio. A ﬂow chart
describing the process of case selection and exclusion is
presented in Figure 4. These mutant cases gave us an
opportunity to examine the association between AI in
ampliﬁcation of CA-SSR1 repeats and AI in the ratio of
mutant to WT alleles. Speciﬁcally, we wished to determine, in
cases having both forms of AI, whether the mutant form was
selectively ampliﬁed in association with selective ampliﬁca-
tion of the shorter allele of CA-SSR1. As described in the
Methods section, we devised methods to determine the ratios
of mutant to WT alleles for the two most frequent mutations,
deletions in exon 19 and the L858R mutation in exon 21,
which together account for ;85% of EGFR mutations in
NSCLC [9]. Of the 109 cases with mutations (in exon 19 or
L858R), sufﬁcient DNA was available from 76. Of these 76
samples, 32 (42.1%) tumors had selective imbalance involving
the mutant allele. The ratio of CA-SSR1 alleles was utilized to
determine whether AI was present and, if present, which of
the two alleles was preferentially overrepresented. Of these
32 samples having AI of the mutant allele, 26 (81.3%) also had
AI of CA-SSR1. In addition, a positive correlation between AI
ratios of CA-SSR1 and mutant/WT ratios was observed in
tumors having either form of mutation (Figure 3). The linear
correlation was tested using Pearson’s correlation and found
to be signiﬁcant. However, because of the possibility that the
observed strong correlation might be driven by extreme
Table 7. Frequencies of AI of Either Allele of CA-SSR1 by Ethnicity
NSCLC Patients AI p-Value
a Mutant or WT EGFR Allele
b AI p-Value
a
All cases (n ¼ 356) 109/356 (30.6%) MT (n ¼ 90) 40/90 (44.4%) 0.002
WT (n ¼ 266) 69/266 (25.9%)
East Asians (n ¼ 205) 73/205 (35.6%) 0.019 MT (n ¼ 73) 34/73 (46.6%) 0.022
WT (n ¼ 132) 39/132 (29.5%)
Individuals of European descent (n ¼ 151) 36/151 (23.8%) MT (n ¼ 17) 6/17 (35.3%) 0.24
WT (n ¼ 134) 30/134 (22.4%)
These analyses were limited to informative cases of East Asians from Japan or Taiwan and individuals of European descent from the US and Australia.
aChi-square test with continuity adjustment.
bMutant (MT) EGFR alleles are limited to exon 19 deletions and exon 21 L858R.
doi:10.1371/journal.pmed.0040125.t007
Table 8. Frequencies of AI of CA-SSR1 by Ethnicity
Cases with AI of CA-SSR1 SAD
a p-Value
b Mutant or WT EGFR Allele
c SAD
a p-Value
b
All cases (n ¼ 109) 60/109 (55.0%) MT (n ¼ 40) 30/40 (75.0%) 0.003
WT (n ¼ 69 30/69 (43.5%)
East Asians (n ¼ 73) 44/73 (60.3%) 0.214 MT (n ¼ 34) 28/34 (82.4%) 0.001
WT (n ¼ 39) 16/39 (41.0%)
Individuals of European descent (n ¼ 36) 16/36 (44.4%) MT (n ¼ 6) 2/6 (33.3%) 0.672
WT (n ¼ 30) 14/30 (46.7%)
These analyses were limited to informative cases of East Asians from Japan or Taiwan and individuals of European descent from the US and Australia.
aNumber of SAD cases (analyses limited to cases with AI).
bChi-square test with continuity adjustment.
cMutant (MT) EGFR alleles are limited to exon 19 deletions and exon 21 L858R.
doi:10.1371/journal.pmed.0040125.t008
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used a nonparametric test instead to compare mutant/WT
ratios between those with SAD and those without. As
expected, for all the mutations under study, the cases with
SAD had higher mean mutant/WT ratios than those without
SAD. These ﬁndings agreed with our hypothesis that in cases
demonstrating CA-SSR1 imbalance, the mutant allele was
more frequently increased in relative copy number compared
to the WT allele.
Discussion
In this report we examined the frequency of three germline
polymorphisms in the EGFR gene in healthy individuals of
different ethnicities, and in non-malignant and malignant
lung tissue from patients with NSCLC. We found ethnic-
related differences in polymorphism frequencies consistent
with previous reports, indicating that the shorter allele of CA-
SSR1 and the minor forms of SNPs  191 (C/A or A/A) and
 216 (G/T or T/T) are signiﬁcantly less frequent in East Asians
than in individuals of European descent [21]. In addition, we
noted a relationship between the presence of the short form
of CA-SSR1 and the minor forms of the SNPs. The published
data [13,19,21,26] and our observations regarding EGFR
mRNA expression in HBECs suggest that the shorter CA-
SSR1 allele lengths and the variant forms of the  191 and
 216 polymorphisms are associated with increased intrinsic
gene expression. However, most of the data in the literature
are from the results of transfection studies or tumor cell lines,
and thus may not reﬂect the state of normal epithelial cells.
As sections of non-malignant lung contain only a small
minority of epithelial cells, a study of adjacent non-malignant
lung tissues from resected cases or peripheral blood cells
would not yield meaningful data. In an attempt to overcome
these limitations, we studied 11 cultures of immortalized
HBECs. These cultures show minimal genetic changes. In the
presence of ligand stimulation, we demonstrated a trend for
increased mRNA expression in lines having the SNP 216 G/T
or T/T genotypes, consistent with published data. The
published reports and our results are consistent with the
hypothesis that cells of individuals of East Asian ethnicity
express less EGFR protein constitutively than cells of
individuals of other ethnicities. However, ﬁnal experimental
proof for this hypothesis is still lacking.
Ampliﬁcation of the EGFR gene is relatively common in
lung and other cancers, and may be associated with mutations
of the TK domain in lung cancers [12] or of the extracellular
domain in glioblastomas [30]. Two recent reports describe a
correlation between copy numbers of the EGFR gene as
measured by ﬂuorescence in situ hybridization (FISH) and
response to TKIs [11,31]. In this study we used allelic size
differences in the CA-SSR1 repeat polymorphism to deter-
mine AI of the gene. AI was observed in 30.2% of informative
cases, a frequency comparable to increased copy number as
detected by FISH analyses [32]. AI was signiﬁcantly more
frequent in East Asians and occurred nearly twice as
frequently in mutant cases than in WT cases. A relationship
between increased copy number by FISH analysis and
mutation has also been described previously [12]. While there
were no signiﬁcant differences in the frequencies of either
the shorter or longer allele being involved in the imbalance
for all of the cases or for all of the mutant cases, in mutant
cases arising in East Asians, the shorter allele was twice as
likely to be preferentially ampliﬁed as the longer allele.
Finally we determined whether the mutant allele was
selectively ampliﬁed in tumors having both mutation and
imbalance. For tumors having deletion mutations in exon 19
or the L858R point mutation in exon 21 (together accounting
for 86.5% of all mutations) we devised methods for
determining the ratio of mutant to WT alleles. Of 76 cases
examined, 42.1% demonstrated imbalance of the mutant
allele. This ﬁgure is consistent with our ﬁnding of an overall
Figure 4. Flow Chart for Examination of the Relationship between AIs of CA-SSR1 Length and EGFR Mutations
doi:10.1371/journal.pmed.0040125.g004
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in mutant cases, and suggests that in mutation-containing
tumors having AI, the mutant allele is the one that is usually
ampliﬁed. Having found, by separate analyses in mutant
cases, that both the shorter CA-SSR1 allele and the mutant
allele were selectively ampliﬁed, we performed a correlation
of these two forms of imbalance and demonstrated a strong
positive association.
Incorporation of our ﬁndings and previously published
data form the basis of a hypothesis suggesting a close
relationship between CA-SSR1 length, SNP  191 polymor-
phism, and SNP  216 polymorphism and EGFR gene
ampliﬁcation. As mentioned above, all three of these poly-
morphisms (shorter CA-SSR1 length and the variant forms of
the two SNPs) are reported to be associated with increased
EGFR production, and they were rarely observed in East
Asians. These ﬁndings suggest that the cells of most East
Asians make less EGFR protein than do the cells of individuals
of other ethnicities. If a certain critical level of EGFR is
required to drive the cell toward a malignant phenotype,
mutations of the TK domain and autonomous activation of
downstream signaling may target East Asians, the subgroup
with possibly lower intrinsic protein production. Also, we
found in East Asians (but not in individuals of European
descent) that mutations target the shorter CA-SSR1 allele
(suggestive of greater protein production) followed by allele-
speciﬁc ampliﬁcation of the mutant allele. As illustrated in
Figure 5, three events target the same allele: (a) shorter CA-
SSR1 repeat length, (b) activating mutation, and (c) selective
ampliﬁcation of the mutant allele. These interactions favor
greater protein production in mutant tumors. A similar
observation was made in glioblastomas, which frequently
contain a mutation or splicing variant resulting in loss of
much of the extracellular domain of EGFR. The variant form
of the allele frequently demonstrated allele-speciﬁc ampliﬁ-
cation [33]. As previously mentioned, FISH technology has
been used to demonstrate that EGFR ampliﬁcation and
mutation often, but not invariably, occur together [12].
Conclusions
The three polymorphisms associated with increased EGFR
protein production (shorter CA-SSR1 length and the variant
forms of SNPs  216 and  191) were found to be rare in East
Asians as compared to individuals of other ethnicities,
suggesting that the cells of East Asians may make relatively
less intrinsic EGFR protein. Interestingly, especially in tumors
from patients of East Asian ethnicity, EGFR mutations were
found to favor the shorter allele of CA-SSR1, and selective
ampliﬁcation of the shorter allele of CA-SSR1 occurred
frequently in tumors harboring a mutation. These distinct
molecular events targeting the same allele would both be
predicted to result in greater EGFR protein production and/
or activity. These ﬁndings may reveal what underlies some of
the ethnic differences observed in mutational frequencies
and responses to TKIs.
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Background. Most cases of lung cancer—the leading cause of cancer
deaths worldwide—are ‘‘non-small cell lung cancer’’ (NSCLC), which has
a very low cure rate. Recently, however, ‘‘targeted’’ therapies have
brought new hope to patients with NSCLC. Like all cancers, NSCLC occurs
when cells begin to divide uncontrollably because of changes
(mutations) in their genetic material. Chemotherapy drugs treat cancer
by killing these rapidly dividing cells, but, because some normal tissues
are sensitive to these agents, it is hard to kill the cancer completely
without causing serious side effects. Targeted therapies specifically
attack the changes in cancer cells that allow them to divide
uncontrollably, so it might be possible to kill the cancer cells selectively
without damaging normal tissues. Epidermal growth factor receptor
(EGRF) was one of the first molecules for which a targeted therapy was
developed. In normal cells, messenger proteins bind to EGFR and
activate its ‘‘tyrosine kinase,’’ an enzyme that sticks phosphate groups
on tyrosine (an amino acid) in other proteins. These proteins then tell the
cell to divide. Alterations to this signaling system drive the uncontrolled
growth of some cancers, including NSCLC.
Why Was This Study Done? Molecules that inhibit the tyrosine kinase
activity of EGFR (for example, gefitinib) dramatically shrink some NSCLCs,
particularly those in East Asian patients. Tumors shrunk by tyrosine
kinase inhibitors (TKIs) often (but not always) have mutations in EGFR’s
tyrosine kinase. However, not all tumors with these mutations respond
to TKIs, and other genetic changes—for example, amplification (multiple
copies) of the EGFR gene—also affect tumor responses to TKIs. It would
be useful to know which genetic changes predict these responses when
planning treatments for NSCLC and to understand why the frequency of
these changes varies between ethnic groups. In this study, the
researchers have examined three polymorphisms—differences in DNA
sequences that occur between individuals—in the EGFR gene in people
with and without NSCLC. In addition, they have looked for associations
between these polymorphisms, which are present in every cell of the
body, and the EGFR gene mutations and allelic imbalances (genes occur
in pairs but amplification or loss of one copy, or allele, often causes allelic
imbalance in tumors) that occur in NSCLCs.
What Did the Researchers Do and Find? The researchers measured
how often three EGFR polymorphisms (the length of a repeat sequence
called CA-SSR1, and two single nucleotide variations [SNPs])—all of which
probably affect how much protein is made from the EGFR gene—
occurred in normal tissue and NSCLC tissue from East Asians and
individuals of European descent. They also looked for mutations in the
EGFR tyrosine kinase and allelic imbalance in the tumors, and then
determined which genetic variations and alterations tended to occur
together in people with the same ethnicity. Among many associations,
the researchers found that shorter alleles of CA-SSR1 and the minor forms
of the two SNPs occurred less often in East Asians than in individuals of
European descent. They also confirmed that EGFR kinase mutations were
more common in NSCLCs in East Asians than in European-descent
individuals. Furthermore, mutations occurred more often in tumors with
allelic imbalance, and in tumors where there was allelic imbalance and an
EGFR mutation, the mutant allele was amplified more often than the
wild-type allele.
What Do These Findings Mean? The researchers use these associations
between gene variants and tumor-associated alterations to propose a
model to explain the ethnic differences in mutational frequencies and
responses to TKIs seen in NSCLC. They suggest that because of the
polymorphisms in the EGFR gene commonly seen in East Asians, people
from this ethnic group make less EGFR protein than people from other
ethnic groups. This would explain why, if a threshold level of EGFR is
needed to drive cells towards malignancy, East Asians have a high
frequency of amplified EGFR tyrosine kinase mutations in their tumors—
mutation followed by amplification would be needed to activate EGFR
signaling. This model, though speculative, helps to explain some clinical
findings, such as the frequency of EGFR mutations and of TKI sensitivity
in NSCLCs in East Asians. Further studies of this type in different ethnic
groups and in different tumors, as well as with other genes for which
targeted therapies are available, should help oncologists provide
personalized cancer therapies for their patients.
Additional Information. Please access these Web sites via the online
version of this summary at http://dx.doi.org/10.1371/journal.pmed.
0040125.
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